Labiotech.eu

News and Trends 28 Sep 2017

Everyone Wants a Piece of this Scottish Biotech’s AI

Evotec has doubled down on its investment in Exscientia: the German outfit just announced it has invested €15M to take a minority stake. Sanofi, GSK and Evotec have all jumped at the opportunity to work with Exscientia, a Scottish startup founded in 2012 and incubating in Dundee. Now, Evotec has gone beyond the initial immuno-oncology deal […]

September 28, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 28 Sep 2017

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

Nightstar has gone public on the American market with the aim of raising $75M for its gene-based retinal disease cures. Spun out from Oxford in 2013, Nightstar is developing and commercializing one-shot gene therapies for various eye diseases that could lead to blindness. This morning, it debuted on the Nasdaq with a projected $75M (£56M / €64M) […]

September 28, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 28 Sep 2017

Study Results Confirm that Abivax’s Treatment Towards an HIV Cure Gets Rid of Virus

Abivax’s HIV cure candidate, ABX464, caused a significant drop in the viral reservoir over an extended period during a Phase IIa study. Abivax targets the immune system to cure viral diseases. The company has announced initial results from the first cohort of patients in its most recent Phase IIa trial testing its potential HIV cure, ABX464. Initial […]

September 28, 2017 - 2 minutesmins - By Alex Dale

Inside Labiotech 28 Sep 2017

Why does Labiotech.eu exist? (Not only to play table football together)

Our mission, since we started Labiotech.eu, has been to empower biotech ecosystems to better cure, feed and fuel the world. In our team, we all believe biotech is an industry that has an enormous impact on making the world a better place (I can’t actually think of any more impactful industry). Bill Gates recently told […]

September 28, 2017 - 3 minutesmins - By Philip Hemme

Interview 28 Sep 2017

Ethical Drug Development can Start with Charity Investors: A Conversation

As the furor over drug pricing has driven the biopharma industry to reflect on its ethics, I sat down with David Pardoe of LifeArc to discuss the involvement of charity investors. In August, a story emerged that Novartis CEO Joe Jimenez not only responded to a patient’s letter but met with him soon thereafter to […]

September 28, 2017 - 6 minutesmins - By Evelyn Warner

Interview 27 Sep 2017

What’s this Top Swiss VC Up To These Days? General Partner Tells All

Philip caught up with Markus Hosang to find out which companies the VC is keeping an eye on after its next round of fundraising. General Partner, Markus Hosang has a strong background in pharma and VC, which serves him well when searching through the bustling biotech industry in Europe. BioMed Partners is a very active […]

September 27, 2017 - 3 minutesmins - By Alex Dale

News and Trends 27 Sep 2017

German Researchers’ Algorithm Can Predict New Targets for Existing Drugs

An algorithm based on the brain’s self-organizing capacity has been developed in Germany that could combat the rising costs of drug development. A team at TU Dresden has pioneered an algorithm that exploits the self-organization of the brain to predict new drug targets, without the need for extra biological or molecular information. The study, published in Briefings […]

September 27, 2017 - 3 minutesmins - By Alex Dale

News and Trends 27 Sep 2017

French Gene Therapy for Wilson’s Disease gets Orphan Status

Vivet Therapeutics has been granted Orphan Drug Designation for its gene therapy for Wilson’s disease, VTX-801, by both the FDA and the European Commission. The French biotech Vivet Therapeutics is developing what could eventually become the first gene therapy for Wilson’s disease. Seeing its potential, both the FDA and the EC have decided to grant […]

September 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Sep 2017

Belgian Pharma’s Single-Tablet HIV Treatment Approved in the EU

Janssen’s single-tablet regimen, Symtuza, has been approved by the European Commission for the treatment of HIV in adults and adolescents in the EU. The pharmaceutical arm of Johnson & Johnson, Janssen, has announced that the European Commission has approved its single-tablet regimen (STR), Symtuza, to treat Human Immunodeficiency Virus (HIV) infections. Previous studies have demonstrated […]

September 27, 2017 - 3 minutesmins - By Alex Dale

News and Trends 27 Sep 2017

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will focus on the development of a drug with potential to significantly improve the treatment of […]

September 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 27 Sep 2017

How to Survive the Valley of Death: Tips from Europe’s Largest Research Hospital

Taking research from the bench to the bedside is an infamous graveyard in biotech. Researchers from Charité and their colleagues have a plan to help startups survive. “Many basic research approaches currently fail far too late in their development,” write researchers from Charité University Hospital, based here in Berlin, in collaboration with colleagues from the University […]

September 27, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2017

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at both hematological cancers and solid tumors. The Series C fundraising of $80M (€68M) is added to £70M (€80M) made in Series A […]

September 26, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Everyone Wants a Piece of this Scottish Biotech’s AI

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

Study Results Confirm that Abivax’s Treatment Towards an HIV Cure Gets Rid of Virus

Why does Labiotech.eu exist? (Not only to play table football together)

Ethical Drug Development can Start with Charity Investors: A Conversation

What’s this Top Swiss VC Up To These Days? General Partner Tells All

German Researchers’ Algorithm Can Predict New Targets for Existing Drugs

French Gene Therapy for Wilson’s Disease gets Orphan Status

Belgian Pharma’s Single-Tablet HIV Treatment Approved in the EU

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

How to Survive the Valley of Death: Tips from Europe’s Largest Research Hospital

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!